440 
HR 3162 PCS
ices are made available under part B of title IV on the 
basis of being a child in foster care’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) shall take effect as if included in the 
amendment made by section 6044(a) of the Deficit Reduc-
tion Act of 2005. 
TITLE IX—MISCELLANEOUS 
SEC. 901. MEDICARE PAYMENT ADVISORY COMMISSION 
STATUS. 
Section 1805(a) of the Social Security Act (42 U.S.C. 
1395b–6(a)) is amended by inserting ‘‘as an agency of 
Congress’’ after ‘‘established’’. 
SEC. 902. REPEAL OF TRIGGER PROVISION. 
Subtitle A of title VIII of the Medicare Prescription 
Drug, Improvement, and Modernization Act of 2003 (Pub-
lic Law 108–173) is repealed and the provisions of law 
amended by such subtitle are restored as if such subtitle 
had never been enacted. 
SEC. 903. REPEAL OF COMPARATIVE COST ADJUSTMENT 
(CCA) PROGRAM. 
Section 1860C–1 of the Social Security Act (42 
U.S.C. 1395w–29), as added by section 241(a) of the 
Medicare Prescription Drug, Improvement, and Mod-
ernization Act of 2003 (Public Law 108–173), is repealed. 
VerDate Aug 31 2005 
02:04 Sep 05, 2007
Jkt 059200
PO 00000
Frm 00440
Fmt 6652
Sfmt 6201
E:\BILLS\H3162.PCS
H3162
bajohnson on PROD1PC71 with BILLS
441 
HR 3162 PCS
SEC. 904. COMPARATIVE EFFECTIVENESS RESEARCH. 
(a) IN GENERAL.—Part A of title XVIII of the Social 
Security Act is amended by adding at the end the fol-
lowing new section: 
‘‘COMPARATIVE EFFECTIVENESS RESEARCH 
‘‘SEC. 1822. (a) CENTER FOR COMPARATIVE EFFEC-
TIVENESS RESEARCH ESTABLISHED.— 
‘‘(1) IN GENERAL.—The Secretary shall estab-
lish within the Agency of Healthcare Research and 
Quality a Center for Comparative Effectiveness Re-
search (in this section referred to as the ‘Center’) to 
conduct, support, and synthesize research (including 
research conducted or supported under section 1013 
of the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003) with respect to the 
outcomes, effectiveness, and appropriateness of 
health care services and procedures in order to iden-
tify the manner in which diseases, disorders, and 
other health conditions can most effectively and ap-
propriately be prevented, diagnosed, treated, and 
managed clinically. 
‘‘(2) DUTIES.—The Center shall— 
‘‘(A) conduct, support, and synthesize re-
search relevant to the comparative clinical effec-
tiveness of the full spectrum of health care 
treatments, including pharmaceuticals, medical 
VerDate Aug 31 2005 
02:04 Sep 05, 2007
Jkt 059200
PO 00000
Frm 00441
Fmt 6652
Sfmt 6201
E:\BILLS\H3162.PCS
H3162
bajohnson on PROD1PC71 with BILLS
442 
HR 3162 PCS
devices, medical and surgical procedures, and 
other medical interventions; 
‘‘(B) conduct and support systematic re-
views of clinical research, including original re-
search conducted subsequent to the date of the 
enactment of this section; 
‘‘(C) use methodologies such as random-
ized controlled clinical trials as well as other 
various types of clinical research, such as obser-
vational studies; 
‘‘(D) submit to the Comparative Effective-
ness Research Commission, the Secretary, and 
Congress appropriate relevant reports described 
in subsection (d)(2); 
‘‘(E) encourage, as appropriate, the devel-
opment and use of clinical registries and the de-
velopment of clinical effectiveness research data 
networks from electronic health records, post 
marketing drug and medical device surveillance 
efforts, and other forms of electronic health 
data; and 
‘‘(F) not later than 180 days after the 
date of the enactment of this section, develop 
methodological standards to be used when con-
ducting studies of comparative clinical effective-
VerDate Aug 31 2005 
02:04 Sep 05, 2007
Jkt 059200
PO 00000
Frm 00442
Fmt 6652
Sfmt 6201
E:\BILLS\H3162.PCS
H3162
bajohnson on PROD1PC71 with BILLS
443 
HR 3162 PCS
ness and value (and procedures for use of such 
standards) in order to help ensure accurate and 
effective comparisons and update such stand-
ards at least biennially. 
‘‘(b) OVERSIGHT BY COMPARATIVE EFFECTIVENESS 
RESEARCH COMMISSION.— 
‘‘(1) IN GENERAL.—The Secretary shall estab-
lish an independent Comparative Effectiveness Re-
search Commission (in this section referred to as the 
‘Commission’) to oversee and evaluate the activities 
carried out by the Center under subsection (a) to en-
sure such activities result in highly credible research 
and information resulting from such research. 
‘‘(2) DUTIES.—The Commission shall— 
‘‘(A) determine national priorities for re-
search described in subsection (a) and in mak-
ing such determinations consult with patients 
and health care providers and payers; 
‘‘(B) monitor the appropriateness of use of 
the CERTF described in subsection (f) with re-
spect to the timely production of comparative 
effectiveness research determined to be a na-
tional priority under subparagraph (A); 
VerDate Aug 31 2005 
02:04 Sep 05, 2007
Jkt 059200
PO 00000
Frm 00443
Fmt 6652
Sfmt 6201
E:\BILLS\H3162.PCS
H3162
bajohnson on PROD1PC71 with BILLS
444 
HR 3162 PCS
‘‘(C) identify highly credible research 
methods and standards of evidence for such re-
search to be considered by the Center; 
‘‘(D) review and approve the methodo-
logical standards (and updates to such stand-
ards) developed by the Center under subsection 
(a)(2)(F); 
‘‘(E) enter into an arrangement under 
which the Institute of Medicine of the National 
Academy of Sciences shall conduct an evalua-
tion and report on standards of evidence for 
such research; 
‘‘(F) support forums to increase stake-
holder awareness and permit stakeholder feed-
back on the efforts of the Agency of Healthcare 
Research and Quality to advance methods and 
standards that promote highly credible re-
search; 
‘‘(G) make recommendations for public 
data access policies of the Center that would 
allow for access of such data by the public while 
ensuring the information produced from re-
search involved is timely and credible; 
‘‘(H) appoint a clinical perspective advisory 
panel for each research priority determined 
VerDate Aug 31 2005 
02:04 Sep 05, 2007
Jkt 059200
PO 00000
Frm 00444
Fmt 6652
Sfmt 6201
E:\BILLS\H3162.PCS
H3162
bajohnson on PROD1PC71 with BILLS
445 
HR 3162 PCS
under subparagraph (A), which shall frame the 
specific research inquiry to be examined with 
respect to such priority to ensure that the infor-
mation produced from such research is clinically 
relevant to decisions made by clinicians and pa-
tients at the point of care; 
‘‘(I) make recommendations for the pri-
ority for periodic reviews of previous compara-
tive effectiveness research and studies con-
ducted by the Center under subsection (a); 
‘‘(J) routinely review processes of the Cen-
ter with respect to such research to confirm 
that the information produced by such research 
is objective, credible, consistent with standards 
of evidence established under this section, and 
developed through a transparent process that 
includes consultations with appropriate stake-
holders; 
‘‘(K) at least annually, provide guidance or 
recommendations to health care providers and 
consumers for the use of information on the 
comparative effectiveness of health care services 
by consumers, providers (as defined for pur-
poses of regulations promulgated under section 
264(c) of the Health Insurance Portability and 
VerDate Aug 31 2005 
02:04 Sep 05, 2007
Jkt 059200
PO 00000
Frm 00445
Fmt 6652
Sfmt 6201
E:\BILLS\H3162.PCS
H3162
bajohnson on PROD1PC71 with BILLS